Trial Information

Summary: PHI-52 NCI#7225: A Phase I and Pharmacokinetic Study of Oral 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine)in the Treatment of Advanced Solid Tumors

You have been asked to participate in this research study because you have advanced cancer that is not felt to benefit from standard treatment.  The purpose of this trial is to find the highest dose of an oral form of an investigational drug called Triapine that can be given to patients without causing unmanageable side effects.  Additional purposes of this study are to investigate the safety of Triapine and to find out what side effects it causes and how the drug interacts with the body.  This study will also measure the levels of certain genes in participants’ tumors that might be related to how people’s bodies react to the drug.  Your treatment on this study is expected to last at least 4 weeks up to several months.  After your treatment on this study is over, your medical condition will be followed indefinitely.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: September 2, 2008 at 1:51:09 PM